Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2013

X-Chem, AstraZeneca Expand Drug Discovery Collab

  • Small molecule-focused drug discovery firm X-Chem has entered into an expanded global drug discovery collaboration with AstraZeneca across all of the pharmaceutical company’s therapeutic areas and multiple target classes.

    The companies entered into a previous collaboration in May of 2012. This new agreement comes just weeks after AstraZeneca elected to license three drug discovery programs resulting from that 2012 effort, directed at an oncology protein-protein interaction target, a respiratory/inflammation PPI target, and an antibacterial target. AstraZeneca has opted to extend the initial research collaboration from two to five years, and X-Chem will conduct drug discovery on at least 10 therapeutic targets per year going forward.

    Per the new agreement, X-Chem will receive committed research and development funding for each project, and each X-Chem program licensed by AstraZeneca is eligible for preclinical, clinical, and sales milestones in the aggregate amount of up to $26 million. In addition, X-Chem will receive royalties for each successfully commercialized drug that results from a licensed collaboration program.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »